Drugs.com - Clinical Trials

Sarepta Therapeutics Shares Safety Update on Elevidys

CAMBRIDGE, Mass., March 18, 2025 -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, shared the following safety update related to Elevidys (delandistrogene moxeparvovec-rokl), the only approved...

Apr 26, 2025 - 14:23
 0
Sarepta Therapeutics Shares Safety Update on Elevidys
CAMBRIDGE, Mass., March 18, 2025 -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, shared the following safety update related to Elevidys (delandistrogene moxeparvovec-rokl), the only approved...
Read More

Tags:

Previous Article

FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer...

Next Article

FDA Warns Consumers Not to Use Counterfeit Ozempic (semaglutide) Found in U.S. D...

Related Posts

Boehringer Ingelheim Starts Phase II Study of its Potential First-in-Class Oral Compound as a Treatment for Geographic Atrophy​

Boehringer Ingelheim Starts Phase II Study of its Poten...

May 6, 2025  0

NIH Researchers Develop Eye Drops That Slow Vision Loss in Animals

NIH Researchers Develop Eye Drops That Slow Vision Loss...

Apr 26, 2025  0

Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension

Mineralys Therapeutics Announces Late-Breaking Data fro...

Apr 26, 2025  0